Post-Plunge: Is Sarepta a Bad News Buy?

From the smallest biotech to the biggest pharmaceutical stock, The Motley Fool's Market Check-Up covers the health care sector's biggest headlines, hottest market movers, and Obamacare's ongoing rollout.

Shares of Sarepta Therapeutics  plunged more than 60% earlier this week on news that Food and Drug Administration thinks it's too early to file a new drug application for its Duchenne muscular dystrophy drug eteplirsen. The market sell-off was also spurred in part by a competing drug in this space from GlaxoSmithKline and Prosensa that failed its phase 3 trials. In this segment from Tuesday's episode, health care analyst David Williamson discusses whether investors who believe in this drug should consider this sell-off a buying opportunity, and why those looking to buy on the dip may need a healthy dose of patience.

One growth stock to watch today
This incredible tech stock is growing twice as fast as Google and Facebook, and more than three times as fast as and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!

Editor's Note: This video was filmed on Nov. 12, 2013.

Follow David on Twitter: @MotleyDavid.

The article Post-Plunge: Is Sarepta a Bad News Buy? originally appeared on

Alison Southwick has no position in any stocks mentioned. David Williamson has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story